GEN Exclusives

More »

GEN News Highlights

More »
Feb 20, 2007

Pro-Pharmaceuticals Works with Chemwerth to Scale Up Davanat

  • Pro-Pharmaceuticals is collaborating with Chemwerth to scale up production of its lead drug candidate, Davanat®, to 100 kilograms for initial marketing needs. 

    Davant is a carbohydrate polymer composed of mannose and galactose (galactomannan). Pro-Pharmaceuticals believes  that its mechanism of action is based upon binding to lectins on the cell surface. It thus theorizes that the product targets specific lectin receptors that are over-expressed on cancer cells.

    Current research indicates that Galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis, and tumor metastasis, according to a Pro-Pharmaceuticals. The company hence believes that this form of targeted delivery may allow for higher doses of chemotherapy administration with no increase in toxicity.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?